- No peptide in this database is established for the menopausal transition, and most of the compounds discussed alongside menopause were never studied by menopausal status at all.
- GHK-Cu has the most menopause-relevant enrollment, because several topical dermatology studies included peri- and postmenopausal women for skin endpoints, not for systemic menopause outcomes.
- Tesamorelin's trials reported a smaller visceral-fat response in women than men, a rare disclosed sex difference that shows why menopause-specific data cannot be assumed from mixed populations.
Menopause is one of the most common transitions in human life and one of the least served by targeted research. That gap creates a vacuum, and vacuums get filled with confident marketing. This page does the opposite. It walks through the peptides that get mentioned around menopause and asks a single unglamorous question of each: was any of the research actually designed to answer a menopausal question? For most of them, the answer is no.
None of the compounds below is an established treatment for menopausal symptoms, and none is a replacement for hormone therapy or medical care. What follows is an evidence map, not a protocol.
The honest state, compound by compound
| Compound | Why it comes up | Menopause-specific evidence |
|---|---|---|
| GHK-Cu | Copper-binding tripeptide studied in topical skin-aging research | Some dermatology studies enrolled peri/postmenopausal women for skin endpoints; no systemic menopause outcomes |
| Tesamorelin | GHRH analog approved for visceral-fat reduction in HIV lipodystrophy | Not studied by menopausal status; trials reported a smaller response in women than men |
| Kisspeptin-10 | Reproductive-axis probe studied directly in women | Studied mostly in reproductive-age women; menopause-specific data is limited |
| Oxytocin | Female-rich literature across reproduction and behavior | Broad female base spans reproductive age; comparatively little in menopause specifically |
| Epitalon | Marketed with pineal and anti-aging framing | No menopause-specific data; human evidence is thin and largely low-quality |
The one with the most menopause-relevant enrollment
If any compound here touches menopausal women deliberately, it is GHK-Cu, and only in a narrow way. Several topical dermatology studies enrolled peri- and postmenopausal women for skin-aging endpoints. That is real female enrollment, but it is about skin in a cosmetic context, not about hot flashes, bone, mood, or metabolic change. Its cosmetic-dermatology literature skews female, yet very few of those studies reported sex-stratified skin outcomes, and evidence for any systemic or injected use is far weaker and largely preclinical.
That tesamorelin finding is worth pausing on, because it is the strongest argument on the whole page. When investigators bothered to look, women responded differently from men. It is contraindicated in pregnancy per its label, was never studied by menopausal status, and its relevance to menopause is entirely inferred. The disclosed sex difference is precisely why inference from mixed-sex or male data is unsafe: sometimes the sexes genuinely diverge, and you only know if someone measured it.
Reproductive-axis compounds are the wrong tool for the wrong stage
Kisspeptin-10 is unusual and valuable because it has been studied directly in women, changing across the menstrual cycle and acting upstream of LH and FSH. But that work sits in reproductive-age fertility and hypothalamic-amenorrhea research. Menopause is defined by the winding down of that very axis, so a reproductive-age GnRH probe has limited menopausal read-across, and menopause-specific data on it is limited. Oxytocin tells a similar story from the other direction: a genuinely female-rich literature that happens to be concentrated in reproductive age, with comparatively little in menopause itself.
Epitalon is often wrapped in pineal and anti-aging framing that sounds tailor-made for menopause. The reality: its human evidence is limited and largely low-quality, much of it from a single research group, with no rigorous independent trials and no female-specific or menopause-specific data. An absence of harm data is not evidence of safety, and pregnancy and lactation safety are entirely unstudied.
What this map is for
The takeaway is not that peptides are useless around menopause; it is that the research to make that judgment mostly does not exist yet. Where women were enrolled, it was usually for a different endpoint or a different life stage, and where a sex difference was measured it sometimes disagreed with the male result. That combination, real biology plus missing menopause data, is the honest center of this topic. Anyone navigating the transition deserves care built on evidence, which for now means clinicians and established therapies rather than compounds studied for other purposes; each profile linked above shows exactly where the female and menopause-specific evidence begins and ends.